Researchers developed a way to test multiple drugs on cells obtained from individual patients with cystic fibrosis


What Is Cystic Fibrosis?

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.

In people with CF, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause the CFTR protein to become dysfunctional.

When the protein is not working correctly, it’s unable to help move chloride — a component of salt — to the cell surface.

Without the chloride to attract water to the cell surface, the mucus in various organs becomes thick and sticky.

In the lungs, the mucus clogs the airways and traps germs, like bacteria, leading to infections, inflammation, respiratory failure, and other complications.

For this reason, minimizing contact with germs is a top concern for people with CF.

In the pancreas, the buildup of mucus prevents the release of digestive enzymes that help the body absorb food and key nutrients, resulting in malnutrition and poor growth.

In the liver, the thick mucus can block the bile duct, causing liver disease.

 In men, CF can affect their ability to have children.

Symptoms of CF

People with CF can have a variety of symptoms, including:

  • Very salty-tasting skin
  • Persistent coughing, at times with phlegm
  • Frequent lung infections including pneumonia or bronchitis
  • Wheezing or shortness of breath
  • Poor growth or weight gain in spite of a good appetite
  • Frequent greasy, bulky stools or difficulty with bowel movements
  • Male infertility

Cystic fibrosis is a devastating disease caused by mutations in a specific gene, known as the CFTR gene.

But not everyone with cystic fibrosis has the same symptoms or responds to drug treatments in the same way.

In a new pilot study, researchers from the University of Cambridge and Yale University developed a novel, straightforward way to test multiple drugs on cells obtained from individual patients with cystic fibrosis, raising the possibility of highly personalized drug treatment.

The test combines high-speed video microscopy with a novel video analysis algorithm to measure the coordinated movement of cilia – hair-like structures covering airway cells that remove mucus from the lungs and upper airways.

In people with cystic fibrosis, thick mucus accumulates in the airways causing chronic infections, which obstruct breathing and disrupt normal ciliary movement.

The research team used their test to study the movement of cilia in cells derived from multiple patients with different cystic fibrosis mutations, comparing those samples to normal cells.

They then measured the response of those cells to six different drug treatments, including ones not currently approved for cystic fibrosis.

The team found that the patients responded differently to the drugs, suggesting that what works for one person might not work for another, even if each carries the same mutation.

Going forward, the researchers hope that their test could be used to recommend more personalized treatments for this life-threatening disease.

Maurizio Chioccioli, a postdoctoral researcher in the Section of Pulmonary, Critical Care, and Sleep Medicine at Yale, is first author of the paper, which is published in Nature Communications.

More information: M. Chioccioli et al. Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells, Nature Communications (2019). DOI: 10.1038/s41467-019-09798-3
Journal information: Nature Communications
Provided by Yale University


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.